Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Bayer AG buy Hiper99

Start price
€84.93
16.05.13 / 50%
Target price
€94.00
06.11.13
Performance (%)
10.70%
End price
€94.02
06.11.13
Summary
This prediction ended on 06.11.13 with a price of €94.02. The prediction had a final performance of 10.70%. Hiper99 has 50% into this prediction

Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.

Performance without dividends (%)
Name 1w 1m 1y 3y
Bayer AG 1.054% 1.054% -54.208% -49.153%
iShares Core DAX® -0.992% -3.231% 11.661% 16.545%
iShares Nasdaq 100 -0.225% -3.339% 36.491% 43.334%
iShares Nikkei 225® -0.736% -7.859% 18.597% 4.253%
iShares S&P 500 -0.509% -2.979% 26.341% 40.911%

Comments by Hiper99 for this prediction

In the thread Bayer AG diskutieren
Prediction Buy
Perf. (%) 10.70%
Target price 94.000
Change
Ends at 06.11.13

Analysten bewerten Bayer positiv

Die Privatbank Berenberg hat das Kursziel für Bayer von 85 auf 94 Euro angehoben und die Einstufung auf "Buy" belassen. Auch nach zuletzt guter Kursentwicklung des Pharmasektors gehe er von weiterem Aufwärtspotenzial der Branchenwerte von zehn Prozent aus, schrieb Analyst Alistair Campbell in einer Studie vom Mittwoch. Der Experte hob seine Kursziele für die Branche an, da er jetzt aus der Forschung der Unternehmen Medikamente in den Studienphasen I und II ebenfalls in die Bewertung einbezieht.

Die Analysten von JP Morgan und der Commerzbank haben ähnliche Kursziele. Das KGV von ca. 14,3 entspricht meiner Meinung nach der Branche und dem  erwartetem, organischem Umwachswachstum.

Prediction Buy
Perf. (%) 10.70%
Target price 94.000
Change
Ends at 06.11.13

(Zielkurs erreicht)